Eczema Trial, Recruiting (NCT03358693)

Eczema Trial, Recruiting NCT03358693 Sponsor: Prof. Dr. Stephan Weidinger Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT03358693 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are able to understand and sign a written consent form, and are willing and able to follow the study's requirements.
A dermatologist (skin doctor) has diagnosed you with a long-term inflammatory skin condition.
You are already receiving a systemic treatment (a medicine that works throughout the whole body, such as a biologic injection or infusion) as part of your normal medical care, used in the approved, standard way.

Who may not be able to join:

You are not able to sign a written consent form or are unable to follow the study's requirements.
You have used medicines that affect the immune system (such as immunosuppressants) or received light therapy (phototherapy) in the 4 weeks before your first study visit.
You have used steroid creams or ointments, or certain other prescribed skin creams (called calcineurin inhibitors), on the specific areas of skin that would be examined in the study, within 1 week before your first study visit.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stephan Weidinger, MD, Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel

Phone: 004943150021101

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03358693

Sponsor: Prof. Dr. Stephan Weidinger

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 004943150021101

More information: https://clinicaltrials.gov/study/NCT03358693

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are able to understand and sign a written consent form, and are willing and able to follow the study's requirements.
A dermatologist (skin doctor) has diagnosed you with a long-term inflammatory skin condition.
You are already receiving a systemic treatment (a medicine that works throughout the whole body, such as a biologic injection or infusion) as part of your normal medical care, used in the approved, standard way.

Who may not be able to join:

You are not able to sign a written consent form or are unable to follow the study's requirements.
You have used medicines that affect the immune system (such as immunosuppressants) or received light therapy (phototherapy) in the 4 weeks before your first study visit.
You have used steroid creams or ointments, or certain other prescribed skin creams (called calcineurin inhibitors), on the specific areas of skin that would be examined in the study, within 1 week before your first study visit.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Prof. Dr. Stephan Weidinger

Registry

ClinicalTrials.gov

Start date

20 January 2017

Est. completion

31 December 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Changes of molecular profiles over time; Changes of molecular profiles associated with disease severity/remission; Changes of molecular profiles associated with treatment; Changes of molecular profiles associated with treatment response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov